Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

Haematologica. 2019 Jan;104(1):e21-e24. doi: 10.3324/haematol.2018.196279. Epub 2018 Aug 3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / metabolism
  • Hodgkin Disease* / pathology
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Proteins
  • Programmed Cell Death 1 Receptor* / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor* / biosynthesis
  • Recurrence
  • Tumor Microenvironment / drug effects*

Substances

  • Antineoplastic Agents
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor